Formycon AG (FSE: FYB) and OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) announced a strategic manufacturing partnership for biosimilars, combining Formycon's development expertise with OneSource's end-to-end biologics manufacturing capabilities. OneSource will provide integrated Drug Substance and Drug Product manufacturing from its facility in Bangalore, India, supporting Formycon's biosimilar programs for global markets.
The collaboration aligns with Formycon's FYB4Growth strategy, which emphasizes cost efficiency and reliable supply chains. Dr. Stefan Glombitza, CEO of Formycon, stated: 'Reliable, scalable and cost-efficient manufacturing is a cornerstone of our FYB4Growth strategy. By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency.'
Neeraj Sharma, Managing Director & CEO of OneSource, highlighted the partnership's potential to expand access to high-quality biologics: 'This partnership brings together Formycon’s development expertise and OneSource’s integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide. It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacturing of world-class biologics.'
Formycon currently markets three biosimilars—FYB201/ranibizumab, FYB202/ustekinumab, and FYB203/aflibercept—and has four pipeline candidates, including FYB206/pembrolizumab and FYB208/dupilumab. The partnership with OneSource is expected to support these and future programs by leveraging OneSource's five manufacturing facilities approved by global regulators such as the US FDA and EMA. This infrastructure, combined with expertise in biologics, sterile injectables, and drug-device combinations, positions OneSource as a strategic partner for Formycon's global supply chain.
Biosimilars are critical for reducing healthcare costs and expanding patient access to biologic therapies. With global biosimilar sales projected to exceed $74 billion by 2030, according to the press release, the partnership addresses the need for scalable, cost-effective manufacturing. Formycon's FYB4Growth strategy includes geographic diversification into high-growth regions like MENA, APAC, and Latin America, where OneSource's India-based operations can offer competitive advantages.
For more details on Formycon's strategy, visit FYB4Growth. Additional information about OneSource is available at OneSource CDMO.
